Most infants hospitalised for RSV-related infections need oxygen support and critical care despite nirsevimab use, with ...

HealthDay News — In a recent study of a population of infants, published online May 6 in Pediatrics, 72% of infants were found to be immunized against respiratory syncytial virus (RSV).

A meta-analysis indicates that the monoclonal antibody nirsevimab offers significant real-world protection against severe ...

After the monoclonal antibody nirsevimab (Beyfortus) became available to prevent respiratory syncytial virus (RSV) in infants ...

A recent study revealed that newborns can be easily protected against respiratory syncytial virus infection by using the ...

Overall, 72% of 36,949 infants were immunized in the 2023-2024 RSV season with either the bivalent RSV prefusion F protein ...

Monoclonal antibody 'nirsevimab' highly effective in preventing severe RSV in infants, reducing hospitalisations and ICU ...

Nirsevimab is a seasonal immunization that targets RSV in infants. As a monoclonal antibody—a protein that can bind to a ...

Monoclonal antibody nirsevimab provides strong real-world protection against severe RSV in infants, suggests meta-analysis ...

"Nirsevimab is highly effective in preventing RSV-related outcomes in infants, with a pooled real-world effectiveness of 83 ...

The U.S. Centers for Disease Control and Prevention (CDC) recommends that all babies be protected from RSV by one of two ...